About Oral Cancer Foundation News Team - A

This author has not yet filled in any details.
So far Oral Cancer Foundation News Team - A has created 2444 blog entries.

Stem cell therapy could offer new hope for defects and injuries to head, mouth

Source: www.newswise.com In the first human study of its kind, researchers found that using stem cells to re-grow craniofacial tissues—mainly bone—proved quicker, more effective and less invasive than traditional bone regeneration treatments. Researchers from the University of Michigan School of Dentistry and the Michigan Center for Oral Health Research partnered with Ann Arbor-based Aastrom Biosciences Inc. in the clinical trial, which involved 24 patients who required jawbone reconstruction after tooth removal. Patients either received experimental tissue repair cells or traditional guided bone regeneration therapy. The tissue repair cells, called ixmyelocel-T, are under development at Aastrom, which is a U-M spinout company. "In patients with jawbone deficiencies who also have missing teeth, it is very difficult to replace the missing teeth so that they look and function naturally," said Darnell Kaigler, principal investigator and assistant professor at the U-M School of Dentistry. "This technology and approach could potentially be used to restore areas of bone loss so that missing teeth can be replaced with dental implants." William Giannobile, director of the Michigan Center for Oral Health Research and chair of the U-M Department of Periodontics and Oral Medicine, is co-principal investigator on the project. The treatment is best suited for large defects such as those resulting from trauma, diseases or birth defects, Kaigler said. These defects are very complex because they involve several different tissue types—bone, skin, gum tissue—and are very challenging to treat. The main advantage to the stem cell therapy is that it uses the patient's own cells to [...]

2012-07-31T14:01:48-07:00July, 2012|Oral Cancer News|
Read More

Oropharyngeal cancer survival better in those with HPV

Source: www.dailyrx.com Author: Laurie Stoneham The human papillomavirus (HPV) causes a number of malignancies, including head and neck and cervical cancers. Oddly enough, being infected with the virus may help those living with oral cancer. Researchers believe that having HPV improves the lifespan of African Americans who have throat cancer, compared to African Americans who do not have the virus. These are the unexpected findings of a group of researchers, led by Maria J. Worsham, PhD, director of research in the Department of Otolaryngology-Head & Neck Surgery at Henry Ford Health System in Detroit. "This study adds to the mounting evidence of HPV as a racially-linked sexual behavior lifestyle risk factor impacting survival outcomes for both African American and Caucasian patients with oropharyngeal cancer," Dr. Worsham said. Oropharyngeal cancer affects part of the throat, including the base of the tongue, tonsils, soft palate (back of the mouth) and the walls of the throat (pharynx). Risk factors for this oral cancer include smoking, drinking alcohol and HPV infection. To look at how HPV status impacted the outlook of throat cancer patients, researchers worked with 118 patients - 67 of whom did not have the virus and 51 individuals who did. A total of 42 individuals in the study were African American. Here's what researchers learned: African Americans were less likely than Caucasians to have the virus (HPV-positive) as are people over the age of 50 HPV-negative patients who didn't have the virus were nearly 3 times (2.9) more likely to die as [...]

2012-07-25T09:51:54-07:00July, 2012|Oral Cancer News|
Read More

Western University profs to test robotic treatment of throat cancer

Source: metronews.ca Author: Josh Elliott Western University professors David Palma and Anthony Nichols will lead a first-ever study to see if robotic surgery can treat throat cancer while avoiding the long-term side effects that come with chemotherapy and radiation. Transoral robotic surgery (TORS) allows doctors to use miniature robotic arms to operate in tight spaces where human hands can’t fit. London has the only TORS program in Canada. Early stage oropharyngeal cancer patients will be randomly assigned standard radiation care, or the new TORS treatment. Doctors will measure long-term side effects and quality of life following both treatments. Oropharyngeal cancer affects the back of the throat. Radiation therapy is effective at controlling the cancer, but some patients still suffer long-term side effects such as dry throat, difficulty swallowing, and hearing loss. “In the U.S., TORS is being used readily in the treatment of oropharyngeal cancer, in spite of the lack of high-level evidence supporting the use,” said Nichols, a head and neck cancer surgeon at London Health Sciences Centre. Palma, a radiation oncologist at LHSC, says the Western study will compare TORS treatment to traditional radiation therapy. “Before we can implement TORS, we need to prove that it meets that standard: Are the cure rates just as good, and are the side effects less?” Nichols sees reason for optimism: “Early studies of TORS show it holds promise to provide good disease control, as well as offer good speech and swallowing outcomes for patients.”

2012-07-18T06:09:13-07:00July, 2012|Oral Cancer News|
Read More

Blacks with throat cancer get harsher therapy

Source: in.reuters.com Author: Frederik Joelving Blacks in the United States with throat cancer are more likely than whites to have surgery that leaves them unable to speak than to get gentler voice-preserving therapy, according to a study. Previous research has found a similar racial disparity in breast cancer treatment, with blacks more often having the entire breast removed instead of just the cancerous lumps. It's unclear why the disparity exists. But study leader Allen Chen, a radiation oncologist at University of California, Davis, said that poverty, less education and deep-rooted historical biases could all be at work. "There could be an underlying distrust among African Americans where they feel anything less than surgery might be considered quote-unquote experimental," Chen told Reuters Health. He referenced the Tuskegee experiment, conducted by the U.S. government from the 1930s into the 1970s, in which black patients with syphilis went untreated despite assurances to the contrary. "That sort of distrust needs to be addressed or alleviated," Chen said, because voice-preserving treatment for throat cancer, based on radiation and drug therapy, is now the standard. His study, published in the Archives of Otolaryngology - Head & Neck Surgery, is based on data from a US cancer registry including nearly 5,400 cases of laryngeal cancer between 1991 and 2008. About 80 percent of whites had voice-preserving treatment, while the rest had their voice box surgically removed - the traditional approach. Among blacks, 75 percent had the gentler therapy. While that's only a five-percent difference, "I think that's [...]

2012-07-18T06:04:33-07:00July, 2012|Oral Cancer News|
Read More

Researchers report early success using saliva to detect oral cancer

Source: www.nih.gov Author: press release Scientists funded by the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health, reported today taking a major step forward in using saliva to detect oral cancer. As published in the current issue of Clinical Cancer Research, the scientists found they could measure for elevated levels of four distinct cancer-associated molecules in saliva and distinguish with 91 percent accuracy between healthy people and those diagnosed with oral squamous cell carcinoma. This so-called "proof-of-principle" study marks the first report in the scientific literature that distinct patterns of "messenger RNA" not only are measurable in saliva but can indicate a developing tumor. Messenger RNA (mRNA) is the molecular intermediate between gene and protein, serving as a chemical record that an individual gene has been expressed. According to David Wong, D.M.D., D.M.Sc., a scientist at the University of California at Los Angeles (UCLA) School of Dentistry and senior author on the paper, it may be possible with further refinement of the test, possibly by including additional cancer-linked mRNAs, to attain the necessary 99 to 100 percent accuracy of commercial diagnostic tests for oral squamous cell carcinoma, the sixth most common cancer in the United States. Wong noted that currently no biochemical or genetic diagnostic tests are commercially available for oral cancer. He also noted that the RNA patterns in saliva may be informative for other cancers and common diseases. "Saliva is a mirror of our blood," said Wong. "We're now conducting our initial [...]

2012-07-13T18:15:21-07:00July, 2012|Oral Cancer News|
Read More

Robots vs. radiation

Source: the-scientist.com Author: Bob Grant Scientists at London, Ontario-based Lawson Health Research Institute have launched the first ever study of the comparative effectiveness of robotic-assisted surgery versus radiation therapy for the treatment of oropharyngeal cancer, or cancer of the back of the throat. Transoral robotic surgery (TORS), a new method for removing tumors from the throat developed in 2004, approved by the US Food and Drug Administration in 2010, and already used in many hospitals in the United States, may be a good way for throat cancer patients to avoid some of radiation therapy’s side effects, which include speech problems, hearing loss, skin discoloration, taste changes, difficulty swallowing, and dry mouth. “Early studies of TORS show it holds promise to provide good disease control, as well as offer good speech and swallowing outcomes for patients,” said London Health Sciences Center (LHSC) head and neck surgeon Anthony Nichols in a statement cialis otc canadianviagras.com. “However, it is important that we conduct a thorough comparison of the two treatments.” Researchers conducting the so-called ORATOR trial will track quality of life, side effects, and survival in cancer patients randomly assigned to receive either TORS or radiation therapy. “Radiation has worked very well for the treatment of these cancers and has set a very high standard for treatment,” said LHSC radiation oncologist David Palma in a statement. “Before we can implement TORS, we need to prove that it meets that standard—are the cure rates just as good, and are the side effects [...]

2012-07-13T17:51:43-07:00July, 2012|Oral Cancer News|
Read More

Demystifying the immortality of cancer cells

Source: http://medicalxpress.com/ Author: In cancer cells, normal mechanisms governing the cellular life cycle have gone haywire. Cancer cells continue to divide indefinitely, without ever dying off, thus creating rapidly growing tumors. Swiss scientists have discovered a protein complex involved this deregulated process, and hope to be able to exploit it to stop tumor formation in its tracks. All our cells come equipped with an automatic self-destruct mechanism; they are programmed to die after a certain number of divisions. This internal clock is of great interest to cancer researchers, because most forms of cancer exhibit a defect in this innate timing mechanism. Cancer cells continue to divide indefinitely, long past the moment at which a normal cell would self-destruct. A team of researchers from professor Joachim Lingner’s laboratory at EPFL has learned how this defect is regulated in a tumor. Post-doctoral researcher Liuh-Yow Chen led the team in publishing an article appearing in the journal Nature on the 4th of July 2012. Their hope is that the discovery will provide new targets for drug therapies to combat the deadly disease. Cellular immortality, which is responsible for cancer formation, hearkens back to a critical function of the cells of the developing embryo. At the ends of every chromosome there is a special sequence of DNA known as a telomere, whose length is governed by the telomerase enzyme. This sequence represents the lifespan of the cell. Every time the cell divides, it is shortened, and when the telomere finally runs out, [...]

2012-07-08T06:54:32-07:00July, 2012|Oral Cancer News|
Read More

People ignorant of cancers caused by smoking

Source: medicalxpress.com Author: CancerResearch UK Cancer Research UK today reveals the shocking level of ignorance about smoking and cancer among the UK public in a comprehensive new survey of more than 4000 people. When asked to select cancers linked to smoking, more than 80 per cent of people did not know there was a link between smoking and eight different cancers. At least two thirds of the 4,099 people surveyed knew smoking caused cancers of the lung, mouth (oral) and throat (larynx and oesophagus). But less than 20 per cent knew tobacco was linked to leukaemia and cancers of the liver, pancreas, bowel (colorectum), kidney, bladder, cervix, and ovary. And less than 40 per cent knew that stomach cancer is linked to smoking. Cigarette smoke contains a toxic cocktail of more than 70 cancer-causing chemicals. When a cigarette is smoked, these chemicals can enter the bloodstream and travel around the body, increasing the risk of cancer in more than a dozen different locations. Professor Robert West, Cancer Research UK’s quit smoking expert, said: “Nearly everyone knows that smoking causes lung cancer. And smokers may often gamble with their chance of developing the disease. The addiction can lead people to reason that they might avoid lung cancer. But the odds aren’t good. And these alarming results show what could be a fatal level of ignorance about the toxic hit list from tobacco. There are only two options to eliminate illness caused by smoking: help smokers to quit and stop young people from [...]

2012-07-04T10:40:48-07:00July, 2012|Oral Cancer News|
Read More

The danger in smokeless tobacco products

Source: www.observer.ug (Uganda, Africa) Author: Racheal Ninsiima Tobacco use is the single most preventable cause of death among adults and is a significant factor for several mouth, throat, lung and heart diseases. It is also a major contributor to morbidity. Globally, the World Health Organisation (WHO) estimates that tobacco causes about 71% of lung cancer, 42% of chronic respiratory diseases, 20% of global tuberculosis incidence and nearly 10% of cardiovascular diseases. But the issue of smokeless products that contain tobacco has for long been ignored. According to Dr Sheila Ndyanabangi, the tobacco control focal point person at the ministry of Health, schoolchildren are also consuming the products. This is because sometimes the ingredients are written in foreign languages which may not be understood by the consumers. What is smokeless tobacco? There are two basic forms of smokeless tobacco: snuff and chewing tobacco. An article ‘smokeless tobacco and how to quit’ on the website www.cancer.org, says snuff is finely ground tobacco packaged in cans and is sold either dry or moist. The nicotine in the snuff is absorbed through the tissues of the mouth as it is placed between the cheek and gum. Snuff is designed to be both “Smoke-free” and “spit-free” and is marketed as a discreet way to use tobacco. Chewed tobacco comes along as long strands of tobacco leaves that are chewed by the user who thereafter spits out the brown liquid (saliva mixed with tobacco). Types of smokeless tobacco Mouth fresheners: The commonest is Kuber. It is [...]

2012-07-04T10:33:00-07:00July, 2012|Oral Cancer News|
Read More

Protein could provide target for new mouth cancer drugs

Source: www.netdoctor.co.uk Author: staff A protein that is overactive in mouth cancer could provide a new target for the development of drugs against the disease, researchers say. Scientists at Cancer Research UK's Cambridge Research Institute have discovered that a protein called FRMD4A is permanently switched on in cancer. Furthermore, the higher the levels of this protein, the more likely the disease is to spread and come back following treatment. Tests carried out in mice have revealed that by blocking FRMD4A, it may be possible to prevent mouth cancer from growing and spreading. Dr Stephen Goldie, whose findings are published in the journal Cancer Research, said: 'What's really exciting about this research is that we already have potential drugs that can be used to target this protein or compensate for the effects that it is having. 'These drugs could offer new options to patients where surgery and chemotherapy hasn't worked or could be used alongside them.' The research team now plan to carry out clinical trials involving these drugs to see if they work in patients with head and neck squamous cell carcinoma - a particularly aggressive form of mouth cancer. There are various types of mouth cancer which affect more than 5,300 people in the UK each year.

2012-07-03T17:47:55-07:00July, 2012|Oral Cancer News|
Read More
© - The Oral Cancer Foundation - Head & Neck Cancer IRS 501(c)3 Charity - 3419 Via Lido #205, Newport Beach, CA 92663 | Disclaimer / Privacy Policy
Go to Top